AIHTA - Publications - Search - Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase

Hintringer, K. (2011): Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 15.

[thumbnail of DSD_HSO_Nr.15.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

Nilotinib, a second generation tyrosine-kinase inhibitor (TKI), reduces the proliferation of BCR-ABL positive chronic myeloid leukemia (CML) cells by inhibiting the BCR-ABL pathway. Since 2007 nilotinib is approved for the 2nd-line therapy of Philadelphia chromosome (Ph+) CML patients in Europe. In September 2010, the EMA granted a positive opinion for the approval of nilotinib for the 1st-line therapy of Ph+ CML in the chronic phase.
The pivotal ENESTnd trial investigated whether nilotinib 300mg or 400mg is more effective as 1st-line therapy in Ph+ CML-CP patients than the current standard of care – imatinib 400mg.
The results of the trial indicate that nilotinib is clinically more effective than imatinib. The rate of major molecular response, the primary endpoint, is 66% (p<0.001) and 62% (p<0.001) in the nilotinib 300mg and 400mg groups respectively in comparison to 40% in the imatinib group. Progression to the accelerated phase or blast crisis occurred more frequent in the control group (4.2%) compared to nilotinib 300mg (0.7%) and nilotinib 400mg (1.2%). The safety profile of these two agents was comparable and is considered to be clinically manageable and acceptable.
Despite these first encouraging interim results, further follow-up is essential to provide information on durability of the responses, quality-of- life and to further investigate the safety profile of nilotinib in the 1st-line therapy of CML.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:Leukemia, chronic myeloid leukemia, philadephia chromosome positive, chronic phase, CML, Ph+ CML-CP, nilotinib, tasigna
Subjects:QZ Pathology > QZ 200-380 Neoplasms.Cysts
WH Hemic and lymphatic systems
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Series Name:DSD: Horizon Scanning in Oncology 15
Deposited on:20 Jan 2011 11:32
Last Modified:15 Jul 2020 17:45

Repository Staff Only: item control page